No | Age group | n | Age, years | Diagnosis | Revisiting the number of patients with mutations in BMPR2 | Country | Refs. | |
---|---|---|---|---|---|---|---|---|
Before | After | |||||||
1 | Adults | 69 | 50 ± 20 | IPAH | 5 | 3 | Taiwan | [16] |
2 | Adults | 45 | 46 ± 15 | IPAH + HPAH | 8 | 7 | Taiwan | [17] |
3 | Adults | 201 | 47 ± 17 | IPAH | 20 | 18 | Germany | [18] |
4 | Adults and children | 46 | 29.5 ± 7 | IPAH | 4 | 2 | Saudi Arabia | [1] |
5 | Adults | 126 | 49 ± 16 | IPAH | 29 | 27 | Netherlands | [19] |
6 | Adults and children | 331 | 28 ± 11 | IPAH | 81 | 66 | China | [20] |
7 | Adults | 191 | 30.7 ± 10.6 | IPAH | 37 | 34 | China | [21] |
8 | Adults | 13 | 33 | IPAH | 1 | 1 | Lebanon | [22] |
9 | Adults | 127 | 42.84 ± 15,22 | IPAH | 24 | 13 | Spain | [23] |
10 | Adults | 81 | 39.0 ± 13.4 | IPAH + HPAH | 14 | 11 | USA | [24] |
11 | Adults | 28 | 49 ± 16 | IPAH | 7 | 3 | Spain | [25] |
12 | Adults | 275 | 40 ± 15 | IPAH + HPAH | 82 | 57 | China | [26] |
13 | Adults and children | 106 | 11.1 ± 10.6 | IPAH + HPAH | 28 | 19 | China | [27] |
14 | Adults | 73 | 42.7 ± 19.8 | IPAH | 16 | 14 | Korea | [28] |
15 | Adults | 82 | Â | IPAH | 15 | 27 | Netherlands | [29] |
16 | Adults | 8 | 42 ± 9 | IPAH | 1 | 1 | Turkey | [30] |
17 | Adults | 217 |  | IPAH + HPAH | 45 | 37 | China | [31] |
18 | Adults | 37 | 50 ± 13 | IPAH + HPAH + PAH-CHD + PVOD + PAH-HHT | 15 | 9 | Germany | [32] |
19 | Adults | 43 | Â | IPAH | 6 | 6 | Japan | [33] |
20 | Adults and children | 40 | 30.4 (6–59) | IPAH | 14 | 14 | Japan | [34] |
21 | Adults and children | 516 |  | IPAH + HPAH | 151 | 114 | France | [35] |
22 | Adults | 117 |  | IPAH + HPAH | 37 | 34 | Japan | [36] |
23 | Adults and children | 44 | 28.5 ± 11.5 | IPAH + HPAH | 23 | 19 | France | [3] |
24 | Adults and children | 203 | Â | IPAH | 31 | 27 | France | [37] |
25 | Adults | 105 | 56.9 ± 14.47 | IPAH + HPAH | NA | 11 | Russia | Own data |